Min Huang
Medical School
University of Chinese Academy of Sciences
Shanghai
Language: Chinese, English
Contact
Cancer Pharmacology Metabolism Immunology Therapy Research Drug Development Oncology Biomarkers Clinical Trials
Areas of Focus
  • Tumor Pharmacology
  • Tumor Metabolism
  • Tumor Immunology
Work Experience
  • 2013-01~Present - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Researcher
  • 2011-10~2012-12 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Associate Researcher
  • 2011-03~2011-09 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences - Assistant Researcher
  • 2008-01~2011-02 - Dana-Farber Cancer Institute, Harvard Medical School - Postdoctoral Fellow
Academic Background & Achievements
  • 2002-09--2007-06 PhD: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
  • 1998-09--2002-06 Bachelor's: China Pharmaceutical University
Publications
  • Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer, Min Huang, 2024
  • Discovery of Novel Drug-like PHGDH Inhibitors to Disrupt Serine Biosynthesis for Cancer Therapy, Min Huang, 2023
  • Global identification of phospho-dependent SCF substrates reveals a FBXO22 phosphodegron and an ERK-FBXO22-BAG3 axis in tumorigenesis, Min Huang, 2022
  • Metabolic Regulation of CD8(+) T Cells: From Mechanism to Therapy, Min Huang, 2022
  • NAMPT-targeting PROTAC promotes antitumor immunity via suppressing myeloid-derived suppressor cell expansion, Min Huang, 2022
  • Making Protein Degradation Visible: Discovery of Theranostic PROTACs for Detecting and Degrading NAMPT, Min Huang, 2022
  • SLC1A1-mediated cellular and mitochondrial influx of R-2-hydroxyglutarate in vascular endothelial cells promotes tumor angiogenesis in IDH1-mutant solid tumors, Min Huang, 2022
  • Antitumor pharmacological research in the era of personalized medicine, Min Huang, 2022
  • Discovery of Novel Pyrrolo2,3-dpyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors, Min Huang, 2022
  • Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer, Min Huang, 2022
Awards
  • China Young Female Scientist Award (2023): National Level
  • WuXi AppTec Life Chemistry Research Award (2017): Other
  • Shanghai Youth May Fourth Medal (2017): Provincial Level
  • Shanghai Women's Innovation New Star Award and Shanghai 'March 8th Red Banner Holder' (2016): Provincial Level
  • Servier Young Pharmacologist Award (2016): Other
  • Zhongyuan Concord Life Medicine Award for Innovation and Breakthrough (2016): Other
  • Lu Jiaxi Young Talent Award, Chinese Academy of Sciences (2013): Ministerial Level
Post a Project

Contact us

Let's talk!
* Required
* Required
* Required
* Invalid email address
By submitting this form, you agree that IoT ONE may contact you with insights and marketing messaging.
No thanks, I don't want to receive any marketing emails from IoT ONE.
Submit

Thank you for your message!
We will contact you soon.